KORU Medical Systems, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration for the use of its FreedomEDGE® syringe infusion system to deliver RYSTIGGO (rozanolixizumab-noli), a subcutaneous therapy developed by UCB for adults with generalized myasthenia gravis (gMG). The newly expanded label now permits administration by healthcare professionals, supporting use beyond home-based care and extending the system’s relevance to clinical infusion centers.

This development marks a strategic shift for KORU Medical Systems from being largely focused on at-home self-administration to encompassing more formal clinical settings. It reinforces the company’s ambition to position the Freedom Infusion System as a versatile platform capable of supporting a broader range of subcutaneous biologics, with implications for specialty infusion markets and clinical workflow integration.

What the clearance signals about the evolution of large-volume subcutaneous delivery platforms

While subcutaneous infusion has long been synonymous with home-based convenience and chronic therapy adherence, the inclusion of clinic-administered use cases for the FreedomEDGE system expands its strategic relevance. The device had historically been marketed as an alternative to intravenous delivery in home settings, particularly for immunoglobulin therapy, where long-term infusion needs require ease-of-use and safety.

The FDA’s acceptance of its role in a healthcare professional-led setting for delivering RYSTIGGO reflects not only the system’s technical robustness but also a broader shift in how subcutaneous delivery platforms are being integrated across care environments. The infusion volume range (3–6 mL) and duration (15–30 minutes) for RYSTIGGO are well within the capabilities of the FreedomEDGE system, but the significance lies in regulatory alignment for professional use.

This makes the system a viable option in clinics that may not yet be equipped for or trained in home-based infusion workflows, particularly in early-cycle treatment before transitioning to patient self-administration. It also allows for bridging protocols between acute care initiation and chronic care continuity.

Why Rystiggo’s delivery profile aligns with subcutaneous infusion standardization trends

RYSTIGGO’s mechanism as a neonatal Fc receptor (FcRn) blocker approved for adults with anti-AChR or anti-MuSK antibody-positive gMG represents a targeted therapeutic innovation, but its delivery profile also speaks to broader biologic trends. With weekly infusions of limited volume and a relatively short duration, it fits neatly within the capabilities of manual, non-electronic infusion systems that do not rely on powered pumps or hospital-grade equipment.

This reduces cost of care, supports decentralized delivery models, and aligns with payer interests in controlling specialty infusion expenditure. KORU Medical’s Freedom system, including the Freedom60 and FreedomEDGE syringe drivers, is well-placed to support these evolving delivery expectations, particularly for niche autoimmune therapies that are high-cost but require consistent adherence and patient engagement.

The clearance also reinforces the importance of device–drug compatibility in driving formulary access and institutional uptake. For pharmaceutical companies developing subcutaneous biologics, alignment with FDA-cleared delivery systems can accelerate time to market and reduce the need for proprietary device development.

What this means for clinicians and specialty infusion centers targeting gMG

Clinicians managing generalized myasthenia gravis face a complex therapeutic landscape where treatment burden, access to specialty drugs, and individual response to antibody-directed therapies vary widely. The option to initiate or continue RYSTIGGO infusions using a portable, FDA-cleared subcutaneous delivery system like FreedomEDGE offers practical advantages.

First, it supports resource optimization in outpatient centers by reducing the infrastructure demands typically associated with IV infusions. Second, it can help streamline scheduling and throughput in busy neuromuscular or immunology clinics. And third, it lays the groundwork for future at-home transition strategies for appropriate patients, which is particularly relevant in gMG where disease progression and treatment response must be closely monitored.

The addition of the FreedomEDGE system to the arsenal of delivery tools available to specialists and infusion nurses may not change the underlying clinical management of gMG, but it could materially influence workflow, throughput, and patient adherence.

Regulatory, reimbursement, and pipeline implications for KORU Medical Systems

With nine subcutaneous drugs now cleared for administration via the Freedom system, KORU Medical Systems has created a meaningful portfolio of biologic-device pairings. The firm’s strategy to broaden use across both home and clinic settings suggests a dual-front growth model: increasing depth within individual indications while expanding breadth across therapeutic areas.

However, regulatory clearance alone does not guarantee market uptake. The company’s ability to demonstrate cost-effectiveness, integration ease, and payer alignment will be critical. Moreover, institutional buyers will assess the system’s track record, training overhead, and compatibility with reimbursement pathways before making adoption decisions.

On the pipeline side, KORU Medical’s engagement with biopharmaceutical sponsors during clinical development may prove to be a differentiator. As more subcutaneous biologics advance through mid- and late-stage trials—particularly in immunology and rare diseases—partnerships that secure device compatibility early could give KORU Medical Systems a defensible commercial advantage.

Observers tracking the company will likely watch for deeper penetration into specialty clinics, expanded label support for other biologics in development, and signals from payers or pharmacy benefit managers regarding preferred delivery configurations.

How competitive dynamics may shift in the subcutaneous delivery device market

The device-enabled delivery space for large-volume subcutaneous therapeutics is witnessing increasing activity, with entrants offering both electromechanical and mechanical systems to cater to biologics with varying viscosity, stability, and administration profiles. Players like West Pharmaceutical Services and Enable Injections are pushing wearable pump solutions, while others are exploring prefilled systems with on-body deployment.

KORU Medical Systems’ Freedom platform—built around syringe infusion with precision flow-rate control—presents a differentiated value proposition. It avoids battery reliance, electronic complexity, and the need for embedded sensors, instead emphasizing mechanical simplicity, portability, and patient-led control.

For now, the 97 percent adherence rate cited across more than 2 million annual infusions suggests a degree of stickiness with existing patients. But sustained differentiation will require continued platform evolution, real-world outcomes data, and the ability to scale operations and service support globally.

The FDA’s clearance for RYSTIGGO delivery adds another anchor use case, but long-term value creation may hinge on how effectively the company can replicate this success across other biologics with complex delivery demands.

What investors and pharma partners will be watching next in KORU Medical’s strategy

From a capital markets perspective, this clearance adds to the narrative of KORU Medical Systems as a platform-based medical device firm with multiple shots on goal. While the subcutaneous infusion market remains niche relative to traditional hospital-based infusion, it is expanding fast enough—particularly in rare disease and immunology pipelines—to warrant institutional interest.

Pharmaceutical partners evaluating device delivery strategies for biologics in development may view KORU Medical Systems as a plug-and-play solution with regulatory precedent. But they will likely assess the platform’s scalability, safety record, and post-marketing support systems before committing to long-term co-commercialization.

Industry observers suggest that further FDA clearances for pipeline therapies, international regulatory alignment (e.g., with EMA or PMDA), and data on clinical workflow efficiencies in infusion centers will be among the key metrics to watch in 2026.

  biologic delivery systems, FDA 510(k), Freedom Infusion System, FreedomEDGE, generalized myasthenia gravis, KORU Medical Systems, rozanolixizumab-noli, RYSTIGGO, subcutaneous infusion, UCB